Also called interventional studies, clinical trials test new treatments or new combinations of treatments. Clinical trials help researchers evaluate the safety and effectiveness of therapies to improve the quality of care for affected individuals. To locate a clinical trial near you, enter your information into the search criteria below.
To display a map and listing of Clinical Trials near you, enter the above Search Criteria
Below is a table with current pediatric and adult clinical trials for familial hypercholesterolemia and homozygous familial hypercholesterolemia.
|Name||Adult or Pediatric||Population||ClinicalTrials.gov Identifier|
|Evolocumab (AMG 145)||Pediatric||Heterozygous FH||NCT02392559 NCT02624869|
|Bempedoic Acid (ETC-1002)||Adults||Heterozygous FH and Statin Intolerant||NCT02991118 NCT02988115|
|IONIS ANGPTL3-LRx||Adults||Heterozygous FH and Homozygous FH||NCT02709850|
|Gemcabene||Adults||Homozygous FH||NCT02722408 NCT02634151|
|Genetic AAV directed hLDLR Gene Therapy||Adults||Homozygous FH||NCT03018678 NCT02651675|
Last update: March 2017
Why participate in FH clinical research?
By participating in clinical research, you will play an active role in your own healthcare and contribute to the greater good. Because FH is a family disorder, clinical research offers hope and the opportunity to have a powerful impact on the lives of your family members and your future generations.
The FH Foundation seeks to (1) encourage the patient community to step forward and participate in FH research and (2) add to the current body of knowledge about FH.
Observational studies are one type of clinical trial. There are no treatments or actions in an observational study. This type of study can help inform how to best diagnose, treat, and manage a disease or a condition.
The FH Foundation’s CASCADE FHTM Registry is an observational study aimed at helping FH individuals and researchers better understand the condition. For this study, patients provide data directly to the FH Foundation about the burden of disease, knowledge of FH, barriers to care, and experiences with current and new therapies.